<DOC>
	<DOCNO>NCT00332709</DOCNO>
	<brief_summary>This prospective , randomize , open-label , two arm phase III trial design evaluate efficacy safety zoledronic acid prevent bone loss postmenopausal woman operable breast cancer receive 4 6 year adjuvant tamoxifen therapy resection tumor . Patients treat letrozole 2.5 mg orally per day letrozole 2.5 mg orally per day combination zoledronic acid 4 mg/6 month infusion . This trial recruit patient United States .</brief_summary>
	<brief_title>Safety/Efficacy Letrozole Monotherapy Combination With Zoledronic Acid Extended Adjuvant Treatment Postmenopausal Patients With Primary Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Compliant postmenopausal woman primary operable breast cancer 4 6 year therapy tamoxifen ( end tamoxifen therapy within last 6 month ) Performance status 02 ( Eastern Cooperative Oncology Group ) Patients without severe osteoporosis study entry No evidence relapse time randomization Adequate function bone marrow , kidney , liver Estrogen progesteronereceptor status negative unknown Completion adjuvant tamoxifen therapy 6 month prior study start Inflammatory breast cancer Current/active dental problem include infection teeth jawbone , dental fixture trauma , current prior diagnosis osteonecrosis jaw , expose bone mouth , slow healing dental procedure . Recent ( within 6 week ) plan dental jaw surgery History diseases influence bone metabolism Paget 's disease primary overactive parathyroid Prior concomitant therapy : chemotherapy within last 12 month , intravenous oral bisphosphonates , systemic corticosteroid , anabolic steroid growth hormone , Tibolone , parathyroid hormone , systemic sodium fluoride drug know affect skeleton ( calcitonin , mithramycin , gallium nitrate ) Patients previous concomitant cancer ( breast cancer ) within past 5 year EXCEPT adequately treat basal squamous cell skin cancer situ cancer cervix . Patients previous cancer ( ) must diseasefree least 5 year . Patients currently receive oral bisphosphonates must discontinue least 3 week prior study start . Additional protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Letrozole</keyword>
	<keyword>extend adjuvant treatment .</keyword>
	<keyword>Postmenopausal woman primary hormone receptor positive breast cancer</keyword>
</DOC>